Stephane Le Bihan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Stephane Le Bihan has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- Colin Collins
Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada
46 shared publications - Nada Lallous
Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada
41 shared publications - Alireza M. Rezakhanlou
Vancouver Prostate Centre, Vancouver, British Columbia, Canada
40 shared publications - Beibei Zhai
Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
40 shared publications - Dennis Brown
Rakovina Therapeutics, Vancouver, British Columbia, Canada
40 shared publications - Fariba Ghaidi
Vancouver Prostate Centre, Vancouver, British Columbia, Canada
40 shared publications
Latest Publications
- Open Access
- 12 February 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (4) , 1774
Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based on KRAS/NF1 Mutational Status
Low-grade serous ovarian carcinoma (LGSOC) usually presents in advanced stages and is associated with a high mortality rate. Clinical trials targeting the MAPK and cell cycle pathways in LGSOC have shown promising results for its treatment, however there is a need to improve efficacy and define predictive biomarkers to guide patient selection for treatment using these agents. We therefore evaluated cell cycle protein expression by immunohistochemistry (IHC) in 186 LGSOC cases, and evaluated the efficacy of the MEK inhibitor, trametinib, in combination with the CDK4/6 inhibitor, palbociclib, in preclinical models of LGSOC. Abnormal p16 expression was observed in 20% of primary and 46% of recurrent tumors, and it was associated with poorer survival (log-rank p = 0.005). Notably, cell lines with increased sensitivity to trametinib were more likely to harbor mutations in KRAS or NF1 and displayed low pRb levels. Palbociclib showed limited efficacy in vitro; however, the combination of palbociclib and trametinib treatment produced synergistic antiproliferative effects in KRAS/NF1-wild-type cell lines, which displayed higher pRb levels. Acquired drug resistance was linked to increased cyclin D1/E1 expression. This study confirms abnormal p16 IHC as a negative prognostic marker in LGSOC and establishes key determinants of sensitivity to CDK4/6 inhibitor-based therapy.
- 12 February 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (4) , 1774
Open AccessDifferential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based on KRAS/NF1 Mutational Status
Low-grade serous ovarian carcinoma (LGSOC) usually presents in advanced stages and is associated with a high mortality rate. Clinical trials targeting the MAPK and cell cycle pathways in LGSOC have shown promising results for its treatment, however there is a need to improve efficacy and define predictive biomarkers to guide patient selection for treatment using these agents. We therefore evaluated cell cycle protein expression by immunohistochemistry (IHC) in 186 LGSOC cases, and evaluated the efficacy of the MEK inhibitor, trametinib, in combination with the CDK4/6 inhibitor, palbociclib, in preclinical models of LGSOC. Abnormal p16 expression was observed in 20% of primary and 46% of recurrent tumors, and it was associated with poorer survival (log-rank p = 0.005). Notably, cell lines with increased sensitivity to trametinib were more likely to harbor mutations in KRAS or NF1 and displayed low pRb levels. Palbociclib showed limited efficacy in vitro; however, the combination of palbociclib and trametinib treatment produced synergistic antiproliferative effects in KRAS/NF1-wild-type cell lines, which displayed higher pRb levels. Acquired drug resistance was linked to increased cyclin D1/E1 expression. This study confirms abnormal p16 IHC as a negative prognostic marker in LGSOC and establishes key determinants of sensitivity to CDK4/6 inhibitor-based therapy.
- 22 December 2025
- Published by Wiley in Histopathology
- Vol. 88 (5) , 1104-1106
Well‐differentiated papillary mesothelial tumour: histologic, molecular and genetic features support a benign clonal neoplasm despite diffuse peritoneal involvement
- 22 December 2025
- Published by Wiley in Histopathology
- Vol. 88 (5) , 1104-1106
Well‐differentiated papillary mesothelial tumour: histologic, molecular and genetic features support a benign clonal neoplasm despite diffuse peritoneal involvement
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Replicates of cell cycle assays and statistics
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Replicates of cell cycle assays and statistics
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Material and Methods S1 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Materials and methods for in vivo toxicity and cellular fluorescence assays
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Material and Methods S1 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Materials and methods for in vivo toxicity and cellular fluorescence assays
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Replicate graphs of spheroid assays and cell fluorescence data
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Replicate graphs of spheroid assays and cell fluorescence data
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Replicate data of DNA damage assays
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Replicate data of DNA damage assays
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Replicate graphs of cell viability assays and comparison of cell viability assay methods
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Replicate graphs of cell viability assays and comparison of cell viability assay methods
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Replicate graphs of HDAC, PARP1, PARP2 and PARylation assays
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Replicate graphs of HDAC, PARP1, PARP2 and PARylation assays
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Blood cell panel counts and weight loss percentage of in vivo toxicity study
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Blood cell panel counts and weight loss percentage of in vivo toxicity study
- Open Access
Longitudinal single-cell RNA sequencing of a neuroendocrine transdifferentiation model reveals transcriptional reprogramming in treatment-induced neuroendocrine prostate cancer
Neuroendocrine transdifferentiation (NEtD) of prostate adenocarcinoma (PRAD) leads to aggressive neuroendocrine prostate cancer (NEPC). The LTL331 patient-derived xenograft (PDX) model consistently progresses to NEPC following castration, mimicking clinical responses to androgen-deprivation therapy. Here we tracked NEtD using longitudinal single-cell RNA sequencing (scRNA-seq) across eight time points in LTL331 from pre- to post-castration. Castration led to the loss of AR-high PRAD cells, expansion of AR-low populations, and emergence of an AR- and NE-negative (AR-/NE-) intermediate state that transitioned into NEPC. We delineate a model in which pre-EMT cells enriched in ciliogenesis and cell-adhesion pathways differentiate into EMT-like populations before branching into distinct ASCL1+ and ASCL1− NEPC states. The EMT-enriched intermediate, marked by progenitor and neural crest stem-cell genes, acts as a transition bridge, suggesting EMT-associated stemness underlies lineage plasticity. A terminal ASCL1-NEPC state also suggests that ASCL1 is not essential for NEPC maintenance. Gene regulatory analysis highlighted key regulators driving NEtD, including MSX1 and ASCL1 in early EMT-like and NEPC states, respectively. These transcriptional states were validated in both patient-derived bulk and scRNA-seq data. Our findings offer insights into intervention strategies to delay or prevent NEtD with the potential of identifying novel prognostic and therapeutic targets.
Open AccessLongitudinal single-cell RNA sequencing of a neuroendocrine transdifferentiation model reveals transcriptional reprogramming in treatment-induced neuroendocrine prostate cancer
Neuroendocrine transdifferentiation (NEtD) of prostate adenocarcinoma (PRAD) leads to aggressive neuroendocrine prostate cancer (NEPC). The LTL331 patient-derived xenograft (PDX) model consistently progresses to NEPC following castration, mimicking clinical responses to androgen-deprivation therapy. Here we tracked NEtD using longitudinal single-cell RNA sequencing (scRNA-seq) across eight time points in LTL331 from pre- to post-castration. Castration led to the loss of AR-high PRAD cells, expansion of AR-low populations, and emergence of an AR- and NE-negative (AR-/NE-) intermediate state that transitioned into NEPC. We delineate a model in which pre-EMT cells enriched in ciliogenesis and cell-adhesion pathways differentiate into EMT-like populations before branching into distinct ASCL1+ and ASCL1− NEPC states. The EMT-enriched intermediate, marked by progenitor and neural crest stem-cell genes, acts as a transition bridge, suggesting EMT-associated stemness underlies lineage plasticity. A terminal ASCL1-NEPC state also suggests that ASCL1 is not essential for NEPC maintenance. Gene regulatory analysis highlighted key regulators driving NEtD, including MSX1 and ASCL1 in early EMT-like and NEPC states, respectively. These transcriptional states were validated in both patient-derived bulk and scRNA-seq data. Our findings offer insights into intervention strategies to delay or prevent NEtD with the potential of identifying novel prognostic and therapeutic targets.